Kim Na Hyun, Kim Chae A, Chung Sae Rom, Chung Ki-Wook, Kim Won Gu, Jeon Min Ji
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
JCEM Case Rep. 2024 Nov 7;2(12):luae208. doi: 10.1210/jcemcr/luae208. eCollection 2024 Dec.
Parathyroid carcinoma is a rare endocrine malignancy for which the primary treatment is surgery; however, 50% of the patients develop local recurrence or distant metastases. No consensus exists on the standard treatment for metastatic parathyroid cancer. Here we report a case of a 41-year-old male with inoperable locally advanced parathyroid carcinoma who was successfully treated with multimodal therapy including radiofrequency ablation (RFA), external beam radiation therapy (EBRT) to the neck, and sorafenib. Eleven months after initiating sorafenib, serum calcium levels were normal, and both the intact PTH level and the size of metastatic lesion remained stable; thus, we decided to discontinue sorafenib. After discontinuation, the disease remained stable for 18 months and continues to be so. Hence, clinicians can consider multimodal treatment with RFA, EBRT, and sorafenib as a treatment option for locally advanced parathyroid carcinoma.
甲状旁腺癌是一种罕见的内分泌恶性肿瘤，其主要治疗方法是手术；然而，50%的患者会出现局部复发或远处转移。对于转移性甲状旁腺癌的标准治疗尚无共识。在此，我们报告一例41岁男性患者，患有无法手术切除的局部晚期甲状旁腺癌，经包括射频消融（RFA）、颈部外照射放疗（EBRT）和索拉非尼在内的多模式治疗后获得成功。开始使用索拉非尼11个月后，血清钙水平正常，完整甲状旁腺激素（PTH）水平和转移灶大小均保持稳定；因此，我们决定停用索拉非尼。停药后，疾病稳定了18个月，目前仍保持稳定。因此，临床医生可考虑将RFA、EBRT和索拉非尼的多模式治疗作为局部晚期甲状旁腺癌的一种治疗选择。
